FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL		
	OMB APPROVAL	

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* KAKKIS EMIL D					2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE]								Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title Other (specify better))					
(Last) (First) (Middle) C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT					3. Date of Earliest Transaction (Month/Day/Year) 02/05/2014								below)	Presider	nt & Cl	below)		
(Street)) (4. If a	Amendmen	t, Date of O	riginal Fi	iled (M	lonth/Day/Yea	ır)	6. Indiv	idual or Joint Form filed Form filed	by One I	Reportir		,			
(City)	(State)	(Zip)													,	3	
			Table I - No	n-Deri	vativ	e Secur	ities Acq	uired,	Disp	osed of, o	or Bene	ficially O	wned					
1. Title of	Security (Ins	tr. 3)		Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		ction Instr.	4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Following Reported		Form:	Direct Indirect tr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)				(msu. 4)	
Common	Stock			02/0	5/201	.4		С		624,240	A	(1)	624,2	240		D		
Common	Stock												2,552,	241		I	By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009	
			Table II -	Deriva	ative	Securiti	es Acqui	ired, D	ispo	sed of, or onvertible	Benefi	cially Owi	ned					
Security or Exercise (Month/Day/Year) if any (Mo			3A. Deemed Execution Date,	4. 5. Transaction Code (Instr. Ac 8)		5. Number of Derivative Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		cisable and ate /ear)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following	ve ies ially	e Ownershi s Form: Direct (D) or Indirec	Beneficial Ownership t (Instr. 4)	
	Security			Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s (Instr. 4)		(i) (iiisti. 4	"	
Series A Preferred Stock	(1)	02/05/2014		С			1,956,686	(1)		(1) Common Stock 6		624,240(2)	\$0.00	0		D		
Warrant to Purchase Series A Preferred Stock (Right to Buy)	\$0.959	02/05/2014		J			260,688 ⁽³⁾	06/16/	2011	06/30/2020	Series A Preferred Stock	260,688	\$0.00	0)	D		
Warrant to Purchase Common Stock (Right to Buy)	\$3.01	02/05/2014		J		83,039 ⁽³⁾		06/11/	2011	06/30/2020	Common Stock	83,039	\$0.00	0)	D		
Warrant to Purchase Series A Preferred Stock (Right to Buy)	\$0.959	02/05/2014		J			78.206 ⁽³⁾	06/16/	2011	06/14/2021	Series A Preferred Stock	78,206	\$0.00	0)	D		
Warrant to Purchase Common Stock (Right to Buy)	\$3.01	02/05/2014		J		24,950 ⁽³⁾		06/16/	2011	06/14/2021	Common Stock	24,950	\$0.00	0)	D		
Warrant to Purchase Series A Preferred Stock (Right to	\$0.959	02/05/2014		J			130,344 ⁽³⁾	06/16/	2011	06/14/2021	Series A Preferred Stock	130,344	\$0.00	0		D		

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		Derivative Acquired Disposed	Derivative Securities Expiration Date (Month/Day/Year) De				d Amount of Underlying Security nd 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned	10. Ownership Form: Direct (D) or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)		
Warrant to Purchase Common Stock (Right to Buy)	\$3.01	02/05/2014		J		41,583 ⁽³⁾		06/16/2011	06/14/2021	Common Stock	41,583	\$0.00	0	D	

Explanation of Responses:

- 1. The Series A Convertible Preferred Stock converted into the Issuer's common stock on a 1 for 3.1345 basis, such that every 3.1345 shares of Series A Convertible Preferred Stock converted into one share of common stock, and had no expiration date.
- $2.\ Reflects\ a\ 1-for -3.1345\ reverse\ stock\ split\ which\ became\ effective\ on\ January\ 17,\ 2014.$
- 3. Immediately prior to the closing of the Issuer's initial public offering, this warrant to purchase shares of Series A Preferred Stock automatically converted on a 1-for-3.1345 basis into a warrant to purchase shares of Common Stock. Disposition of Warrant to Purchase Series A Preferred Stock and acquisition of Warrant to Purchase Common Stock listed solely for the purpose of reporting such conversion of the shares underlying the security.

Remarks:

By: /s/ Ryan Murr by power of attorney for Emil D. Kakkis, 02/06/2014 M.D., Ph.D.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.